ASP Isotopes Inc. (ASPI) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ASPI SEC filings page.
ASP Isotopes Inc. (ASPI) reported $30.9M in revenue over the twelve months to Jun 30, 2026, up 573.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is funding expansion while weaker margins and ongoing cash use keep operations from funding growth.
FY2025's much larger sales base coincided with gross margin falling to14.3% from38.6% in FY2024. That pairing suggests expansion brought a less favorable cost or revenue mix, rather than simply spreading fixed costs over more sales.
FY2025 financing supplied
Cash conversion is materially different from reported earnings: the net loss was
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of ASP Isotopes Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
ASP Isotopes Inc. held $332.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $37.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and ASP Isotopes Inc. scores 75/100 among other emerging companies.
ASP Isotopes Inc. had 126M shares outstanding at the end of fiscal year 2025, against 72M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and ASP Isotopes Inc. scores 17/100 among other emerging companies.
ASP Isotopes Inc. spent $12.4M on research and development in fiscal year 2025, which was 14.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and ASP Isotopes Inc. scores 45/100 among other emerging companies.
ASP Isotopes Inc. reported revenue of $23.8M in fiscal year 2025, against $4.1M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and ASP Isotopes Inc. scores 97/100 among other emerging companies.
ASP Isotopes Inc.'s operations used $37.8M of cash in fiscal year 2025, against $16.7M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and ASP Isotopes Inc. scores 5/100 among other emerging companies.
ASP Isotopes Inc.'s cash, cash equivalents and investments came to $332.9M at the end of fiscal year 2025, against $235.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and ASP Isotopes Inc. scores 67/100 among other emerging companies.
ASP Isotopes Inc. scores 0.84, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($374.1M) relative to total liabilities ($235.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
ASP Isotopes Inc. passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
ASP Isotopes Inc. reported a net loss of $159.8M while operations used $37.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
ASP Isotopes Inc. reported an operating loss of $59.9M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
ASP Isotopes Inc. generated $5.1M in revenue in Q2 2026. This represents an increase of 327.6% from the same quarter a year earlier. Against the prior quarter it is up 22.6%.
ASP Isotopes Inc.'s EBITDA was -$33.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 188.4% from the same quarter a year earlier. Against the prior quarter it is down 51.1%.
ASP Isotopes Inc. reported -$34.0M in net income in Q2 2026. This represents an increase of 54.8% from the same quarter a year earlier. Against the prior quarter it is down 377.4%.
ASP Isotopes Inc. earned -$0.27 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 350.0%.
Cash & Balance Sheet
ASP Isotopes Inc. recorded an outflow of $27.4M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 182.7% from the same quarter a year earlier. Against the prior quarter it is down 14.8%.
ASP Isotopes Inc. held $219.6M in cash against $5.3M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
ASP Isotopes Inc.'s gross margin was 28.9% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 18.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 11.0 percentage points.
ASP Isotopes Inc.'s ROE was -12.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 285.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 10.4 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
ASP Isotopes Inc. invested $6.8M in research and development in Q2 2026. This represents an increase of 675.5% from the same quarter a year earlier. Against the prior quarter it is up 29.7%.
ASP Isotopes Inc. invested $4.1M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 127.3% from the same quarter a year earlier. Against the prior quarter it is down 33.4%.
Not reported for Q2 2026.
ASPI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1M+327.6% | $4.2M+279.3% | $16.7M+1295.7% | $4.9M+349.5% | $1.2M+17.2% | $1.1M+31.1% | $1.2M | $1.1M |
| Cost of Revenue | $3.6M+481.9% | $2.5M+224.4% | $14.6M+2376.8% | $4.5M+462.7% | $626K+4.1% | $775K+38.0% | $589K | $794K |
| Gross Profit | $1.5M+158.7% | $1.7M+409.5% | $2.1M+244.2% | $423K+43.9% | $572K+35.9% | $327K+17.3% | $605K | $294K |
| R&D Expenses | $6.8M+675.5% | $5.3M+244.0% | $6.8M+383.7% | $3.1M+199.5% | $880K+85.9% | $1.5M+611.2% | $1.4M | $1.0M+332.5% |
| SG&A Expenses | $28.9M+147.4% | $21.3M+215.5% | $17.5M+43.8% | $12.3M+161.9% | $11.7M+57.5% | $6.7M+1194.3% | $12.2M | $4.7M+26.6% |
| Operating Income | -$34.2M-185.7% | -$24.9M-213.0% | -$25.0M-227.1% | -$15.0M-175.5% | -$12.0M-60.5% | -$8.0M-36.8% | -$7.6M | -$5.4M-37.7% |
| EBITDA | -$33.0M-188.4% | -$21.8M-179.8% | -$24.1M | -$14.7M | -$11.4M-56.5% | -$7.8M-36.6% | N/A | N/A |
| Interest Expense | $1.8M+65652.4% | $1.7M+25783.2% | $0+100.0% | $0 | $3K-96.1% | $7K-51.6% | -$65K | $0 |
| Income Tax | -$97K-202.1% | -$31K+56.3% | $184K+20.3% | $74K+979.7% | $95K+590.0% | -$71K-49.1% | $153K | -$8K |
| Net Income | -$34.0M+54.8% | -$7.1M+15.8% | -$63.3M-586.8% | -$12.9M-75.3% | -$75.2M-746.2% | -$8.5M-21.5% | -$9.2M | -$7.4M-74.2% |
| EPS (Basic) | -$0.27+73.8% | -$0.06+50.0% | -$0.84-546.2% | -$0.15-25.0% | -$1.03-329.2% | -$0.12+25.0% | -$0.13-44.4% | -$0.12+14.3% |
| EPS (Diluted) | -$0.27 | -$0.06 | -$0.84-546.2% | -$0.15-25.0% | -$1.03 | -$0.12 | -$0.13-44.4% | -$0.12 |
| Diluted Shares (Avg) | 123M | 121M | N/A | 89M+43.9% | 73M | 69M | N/A | 62M |
ASPI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $572.0M+320.9% | $587.7M+546.7% | $498.0M+427.9% | $225.9M+168.5% | $135.9M+148.2% | $90.9M+100.2% | $94.3M+242.6% | $84.1M+608.6% |
| Current Assets | $272.2M+167.9% | $308.7M+423.0% | $399.9M+508.3% | $174.0M+210.3% | $101.6M+216.8% | $59.0M+125.5% | $65.7M+525.5% | $56.1M+1955.6% |
| Cash & Equivalents | $219.6M+224.5% | $207.3M+270.5% | $279.6M+351.7% | $113.9M+120.9% | $67.7M+139.5% | $56.0M+134.3% | $61.9M+682.7% | $51.6M+2155.2% |
| Short-Term Investments | $35.3M | $83.2M | $47.7M | $0 | $0 | $0 | $0 | $0 |
| Inventory | $1.5M+46.0% | $1.4M+299.5% | $1.1M+1563.6% | $1.4M+1516.6% | $1.0M | $343K | $66K | $85K |
| Accounts Receivable | $3.0M+368.4% | $2.4M+245.7% | $1.1M+52.5% | $17.4M+3009.3% | $649K+26.0% | $692K+95.5% | $707K+226.6% | $560K+21.8% |
| Long-Term Investments | $19.4M | $15.6M | $5.6M | $5.0M | $0 | $0 | $0 | $0 |
| Goodwill | $6.5M+92.3% | $6.4M+96.0% | $5.2M+63.4% | $6.8M+97.9% | $3.4M+2.2% | $3.3M-0.8% | $3.2M-3.0% | $3.5M+8.0% |
| Total Liabilities | $297.3M+176.3% | $288.7M+539.4% | $235.1M+444.5% | $129.3M+207.0% | $107.6M+166.4% | $45.1M+39.5% | $43.2M+395.7% | $42.1M+1203.1% |
| Current Liabilities | $70.3M+918.0% | $70.4M+759.7% | $32.7M+363.2% | $28.3M+281.4% | $6.9M-13.8% | $8.2M+11.6% | $7.1M+24.4% | $7.4M+185.4% |
| Non-Current Liabilities | $227.0M+125.4% | $218.3M+490.6% | $202.4M+460.4% | $101.0M+191.1% | $100.7M+210.9% | $37.0M+47.7% | $36.1M+1089.3% | $34.7M+5403.5% |
| Long-Term Debt | $5.3M | $5.1M | $1.5M+2.1% | $1.5M | N/A | N/A | $1.4M | N/A |
| Total Equity | $264.7M+949.0% | $289.0M+579.8% | $204.2M+326.2% | $74.1M+91.4% | $25.2M+129.1% | $42.5M+304.2% | $47.9M+193.9% | $38.7M+347.9% |
| Retained Earnings | -$272.8M-95.3% | -$238.5M-269.1% | -$231.3M-311.7% | -$152.6M-224.6% | -$139.7M-251.7% | -$64.6M-109.9% | -$56.2M-135.6% | -$47.0M-138.8% |
ASPI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$23.3M-195.3% | -$17.8M-460.3% | -$17.9M-374.7% | -$8.9M-83.0% | -$7.9M-54.2% | -$3.2M-6.7% | -$3.8M-82.8% | -$4.8M-640.9% |
| Depreciation & Amortization | $1.2M+126.8% | $3.1M+1951.7% | $937K+1964.6% | $296K | $530K+261.8% | $149K+44.4% | $45K+24.4% | N/A |
| Stock-Based Compensation | $4.5M+2.6% | $4.4M+133.4% | N/A | $4.5M+116.8% | $4.4M+75.9% | $1.9M+10.3% | N/A | $2.1M-0.2% |
| Capital Expenditures | $4.1M+127.3% | $6.1M+165.8% | $2.4M+81.3% | $3.1M-29.8% | $1.8M-31.4% | $2.3M+85.3% | $1.3M+15.9% | $4.5M+558.0% |
| Free Cash Flow | -$27.4M-182.7% | -$23.9M-336.2% | -$20.2M-298.4% | -$12.0M-28.8% | -$9.7M-25.2% | -$5.5M-29.9% | -$5.1M-58.9% | -$9.3M-598.6% |
| Investing Cash Flow | $40.0M+225.8% | -$97.2M-4019.7% | -$75.2M-2389.8% | -$1.5M+66.5% | -$31.7M-1110.8% | -$2.4M-89.4% | -$3.0M-139.1% | -$4.5M-558.0% |
| Financing Cash Flow | -$2.5M-104.9% | $43.2M+19285.8% | $264.1M+1392.8% | $56.7M+74.9% | $51.0M+319.8% | -$225K-101.1% | $17.7M+99.0% | $32.4M |
| Dividends Paid | N/A | N/A | $0-100.0% | $0 | N/A | N/A | $341 | $0 |
Not reported in any period shown, so not listed: Share Buybacks.
ASPI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 28.9%-18.9pp | 39.9%+10.2pp | 12.5%-38.2pp | 8.6%-18.4pp | 47.8%+6.6pp | 29.7%-3.5pp | 50.7% | 27.0% |
| Operating Margin | -667.5% | -595.4% | -150.2% | -306.1% | -999.1% | -721.6% | -640.7% | -499.5% |
| Net Margin | -663.5% | -170.4% | -380.1% | -263.7% | -6273.5% | -767.9% | -772.5% | -676.2% |
| Return on Equity | -12.8%+285.0pp | -2.5%+17.4pp | -31.0%-11.8pp | -17.4%+1.6pp | -297.9%-217.2pp | -19.9%+46.3pp | -19.3% | -19.0%+29.9pp |
| Return on Assets | -5.9%+49.4pp | -1.2%+8.1pp | -12.7%-3.0pp | -5.7%+3.0pp | -55.3%-39.1pp | -9.3%+6.0pp | -9.8% | -8.7%+26.8pp |
| Current Ratio | 3.87-10.8x | 4.39-2.8x | 12.23+2.9x | 6.14-1.4x | 14.72+10.7x | 7.21+3.6x | 9.31+7.5x | 7.55+6.5x |
| Debt-to-Equity | 0.02-4.2x | 0.02-1.0x | 0.010.0x | 0.02-1.1x | 4.26+0.6x | 1.06-2.0x | 0.03-0.5x | 1.09+0.7x |
| Asset Turnover | 0.010.0x | 0.010.0x | 0.030.0x | 0.020.0x | 0.010.0x | 0.010.0x | 0.01 | 0.010.0x |
| FCF Margin | -535.3% | -571.7% | -121.5% | -245.5% | -809.7% | -497.2% | -425.8% | -857.3% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| ASP Isotopes Inc. ASPI | FY2025 | $23.8M | -$159.8M | N/A | $374.1M | 51/100 |
| TRONOX LIMITED CL A TROX | FY2025 | $2.9B | -$470.0M | -16.2% | $555.8M | 30/100 |
| WESTLAKE CHEMICAL PARTNERS LP WLKP | FY2025 | $1.2B | $48.7M | 4.2% | $743.0M | 73/100 |
| Green Plains, Inc. GPRE | FY2025 | $2.1B | -$121.3M | -5.8% | $1.0B | 26/100 |
| LSB INDUSTRIES INC LXU | FY2025 | $615.2M | $24.6M | 4.0% | $706.3M | 44/100 |
| REX American Resources Corp. REX | FY2025 | $650.5M | $83.0M | 12.8% | $1.4B | 37/100 |
Where ASP Isotopes Inc. Ranks
Frequently Asked Questions
What is ASP Isotopes Inc.'s annual revenue?
ASP Isotopes Inc. (ASPI) reported $23.8M in total revenue for fiscal year 2025. This represents a 475.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ASP Isotopes Inc.'s revenue growing?
ASP Isotopes Inc. (ASPI) revenue grew by 475.5% year-over-year, from $4.1M to $23.8M in fiscal year 2025.
Is ASP Isotopes Inc. profitable?
No, ASP Isotopes Inc. (ASPI) reported a net income of -$159.8M in fiscal year 2025.
What is ASP Isotopes Inc.'s EBITDA?
ASP Isotopes Inc. (ASPI) had EBITDA of -$58.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does ASP Isotopes Inc. have?
As of fiscal year 2025, ASP Isotopes Inc. (ASPI) had $279.6M in cash and equivalents against $1.5M in long-term debt.
What is ASP Isotopes Inc.'s gross margin?
ASP Isotopes Inc. (ASPI) had a gross margin of 14.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is ASP Isotopes Inc.'s return on equity (ROE)?
ASP Isotopes Inc. (ASPI) has a return on equity of -78.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is ASP Isotopes Inc.'s free cash flow?
ASP Isotopes Inc. (ASPI) recorded an outflow of $47.4M in free cash flow during fiscal year 2025. This represents a -79.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is ASP Isotopes Inc.'s operating cash flow?
ASP Isotopes Inc. (ASPI) recorded an outflow of $37.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are ASP Isotopes Inc.'s total assets?
ASP Isotopes Inc. (ASPI) had $498.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are ASP Isotopes Inc.'s capital expenditures?
ASP Isotopes Inc. (ASPI) invested $9.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does ASP Isotopes Inc. spend on research and development?
ASP Isotopes Inc. (ASPI) invested $12.4M in research and development during fiscal year 2025.
What is ASP Isotopes Inc.'s current ratio?
ASP Isotopes Inc. (ASPI) had a current ratio of 12.23 as of fiscal year 2025, which is generally considered healthy.
What is ASP Isotopes Inc.'s debt-to-equity ratio?
ASP Isotopes Inc. (ASPI) had a debt-to-equity ratio of 0.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is ASP Isotopes Inc.'s return on assets (ROA)?
ASP Isotopes Inc. (ASPI) had a return on assets of -32.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is ASP Isotopes Inc.'s P/E ratio?
ASP Isotopes Inc. (ASPI) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $374.1M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ASP Isotopes Inc.'s price-to-sales ratio?
ASP Isotopes Inc. (ASPI) trades at 12.1x sales, its market capitalization divided by revenue of $30.9M revenue, trailing 12 months to June 30, 2026. The market capitalization is $374.1M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does ASP Isotopes Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, ASP Isotopes Inc. (ASPI) held $332.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $37.8M over that year. Dividing the one by the other, the reported balance equals about 106 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is ASP Isotopes Inc.'s Altman Z-Score?
ASP Isotopes Inc. (ASPI) has an Altman Z-Score of 0.84, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is ASP Isotopes Inc.'s Piotroski F-Score?
ASP Isotopes Inc. (ASPI) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ASP Isotopes Inc.'s earnings high quality?
ASP Isotopes Inc. (ASPI) reported a net loss of $159.8M while operations used $37.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can ASP Isotopes Inc. cover its interest payments?
ASP Isotopes Inc. (ASPI) reported an operating loss of $59.9M against $9K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is ASP Isotopes Inc.?
ASP Isotopes Inc. (ASPI) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.